Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02966665 · ClinicalTrials.gov registry record · Phase 1

: Vascular Function in Health and Disease

A Phase 1 study of Hypertension and Heart Failure, sponsored by Russell Richardson.

Recruiting
Registry status
Phase 1
Development phase
420
Enrollment target
1
Study location

NCT02966665: Recruiting Phase 1 study of Hypertension and Heart Failure, sponsored by Russell Richardson.

NCT02966665 is a Phase 1 study of Hypertension and Heart Failure that is actively recruiting participants, run by Russell Richardson. The registered enrollment target is 420 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02966665, a Phase 1 study of Hypertension and Heart Failure, is actively recruiting participants, sponsored by Russell Richardson.

RECRUITING
Registry status
Phase 1
Development phase
420 participants
Enrollment target
1
Study location

Study Summary

Many control mechanisms exist which successfully match the supply of blood with the metabolic demand of various tissues under wide-ranging conditions. One primary regulator of vasomotion and thus perfusion to the muscle tissue is the host of chemical factors originating from the vascular endothelium and the muscle tissue, which collectively sets the level of vascular tone. With advancing age and in many disease states, deleterious adaptations in the production and sensitivity of these vasodilator and vasoconstrictor substances may be observed, leading to a reduction in skeletal muscle blood flow and compromised perfusion to the muscle tissue. Adequate perfusion is particularly important during exercise to meet the increased metabolic demand of the exercising tissue, and thus any condition that reduces tissue perfusion may limit the capacity for physical activity. As it is now well established that regular physical activity is a key component in maintaining cardiovascular health with advancing age, there is a clear need for further studies in populations where vascular dysfunction is compromised, with the goal of identifying the mechanisms responsible for the dysfunction and exploring whether these maladaptations may be remediable. Thus, to better understand the etiology of these vascular adaptations in health and disease, the current proposal is designed to study changes in vascular function with advancing age, and also examine peripheral vascular changes in patients suffering from chronic obstructive pulmonary disease (COPD), Sepsis, Pulmonary Hypertension, and cardiovascular disease. While there are clearly a host of vasoactive substances which collectively act to govern vasoconstriction both at rest and during exercise, four specific pathways that may be implicated have been identified in these populations: Angiotensin-II (ANG-II), Endothelin-1 (ET-1), Nitric Oxide (NO), and oxidative stress.

Primary Outcome

Change in local limb blood flow as measured by ultrasound Doppler in units of milliliters per minute (mL/min) from baseline to up to 1 hour following study interventions

Interventions

  • OTHER Maximum Exercise Tests
  • DRUG BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate
  • DRUG BQ-123
  • DRUG Fexofenadine, Ranitidine
  • OTHER Angiotensin-II, Valsartan

Study Locations (1)

Utah

  • George E Wahlen VA Medical Center - Salt Lake City

Trial Details

FieldValue
Enrollment Target 420 participants
Start Date 2008-09
Est. Completion 2026-08
Phase Phase 1
Russell Richardson

1 total trials

What NCT02966665 shows while recruiting

NCT02966665 is an interventional study that assigns participants to a tested intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (88% lower).

The record links to 4 conditions, with Hypertension appearing as the primary indexed condition, and to 5 interventions - of which Maximum Exercise Tests is the first listed.

NCT02966665 reports a single indexed study location in Utah.

Frequently Asked Questions

What is clinical trial NCT02966665 about?

NCT02966665 is a clinical study titled ": Vascular Function in Health and Disease". Many control mechanisms exist which successfully match the supply of blood with the metabolic demand of various tissues under wide-ranging conditions. One primary regulator of vasomotion and thus perfusion to the muscle tissue is the host of chemical factors originating from the vascular endothelium...

What is the current status of trial NCT02966665?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 420 participants. The study started on 2008-09. Estimated completion is 2026-08.

What conditions does trial NCT02966665 study?

This clinical trial studies the following conditions: Hypertension, Heart Failure, Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension.

What interventions are being tested in trial NCT02966665?

The interventions under investigation include: Maximum Exercise Tests (OTHER), BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate (DRUG), BQ-123 (DRUG), Fexofenadine, Ranitidine (DRUG), Angiotensin-II, Valsartan (OTHER).

Who is sponsoring clinical trial NCT02966665?

This trial is sponsored by Russell Richardson, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02966665 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02966665's enrollment target sits among peer trials

420 143rd of 470 higher than 328 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01790152 · 420 participants

    Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • NCT02701244 · 420 participants

    A Registry Study of Breast Microseed Treatment

  • NCT04149743 · 420 participants · NA

    HEMOTAG® Assessment for Short-term Outcomes of Heart Failure

  • NCT05097976 · 420 participants · Phase 4

    Medrol Dosepak for Outpatient Total Knee Arthroplasty

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02966665, the US trial registry maintained by the National Library of Medicine. NCT02966665 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.